Skip to main content
Rodrigo Dienstmann on Muck Rack

Rodrigo Dienstmann

Barcelona
As seen in: JCO- Precision Oncology, Nature, Wiley Online Library, Frontiers in Immunology, MDPI, Cell Reports Medicine, The Lancet, ESMO Daily Reporter, Future Medicine, Cancer Treatment Reviews
MD/MBA, Medical Director Oncoclínicas Precision Medicine, Oncology Data Scientist at VHIO Digital Health. Views my own. Advisory/speaker Roche and others.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rodrigo

Contact Rodrigo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer

|
By Laia Monserrat, Cristina E. Molina, Andreu Òdena, Irene Agustí-Barea, Cristina Viaplana, Aerica Nagornyuk, Marta Guzman, Olga Rodriguez, Fara Brasó-Maristany, Eduardo García-Galea, Rodrigo Dienstmann, Motoki Takaku, Aleix Prat, Sarat Chandarlapaty, Julia Ponomarenko, Cristina Saura, Mafalda Oliveira, Lara Nonell, Meritxell Bellet, Violeta Serra, Judith García-García, Taras Yuziv Duda, Gilles Flamen, Ruth Maldonado-Padrol, Claudia Yáñez-Bartolomé, Flaminia Pedretti, Guillermo P. Vicent
| Nature Verified
Abstract The androgen receptor (AR) is expressed in 75% of estrogen receptor-positive (ER+) breast cancers (BC). Selective AR modulators (SARMs), like EP0062, present a promising therapeutic strategy for ER + BC, particularly in patients who cannot tolerate endocrine therapy (ET) or whose tumors have developed resistance. We aimed to study the antitumor activity of EP0062 in ER+ patient-derived xenograft (PDX) models.
Open in Who Shared Issue with article?

TrialMatchAI: an end-to-end AI-powered clinical trial recommendation system to streamline patient-to-trial matching

|
By Sigve Nakken, Mariska Bierkens, Johanna Galvis, Slim Karkar, Lana Meiqari, Steve Canham, Rodrigo Dienstmann, Remond J.A. Fijneman, Eivind Hovig, Gerrit A. Meijer, Macha Nikolski, Majd Abdallah, Mikaël Georges, Alexis Groppi, Maria Alexandra Rujano
| Nature Verified
Abstract Patient recruitment remains a major bottleneck in clinical trials, calling for scalable and automated solutions. We present TrialMatchAI, an AI-powered recommendation system that automates patient-to-trial matching by processing heterogeneous clinical data, including structured records and unstructured physician notes.
Open in Who Shared Issue with article?

Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer

|
By Annette M. Byrne, Rodrigo Dienstmann, Eduardo García-Galea
| Wiley Online Library Verified
CC colon cancer CT core of tumor DFS disease-free survival dMMR deficient mismatch repair FFPE formalin-fixed paraffin-embedded IHC immunohistochemistry IM invasive margin IS Immunoscore® ISIC Immunoscore Immune-Checkpoint MCP microenvironment cell populations MSI microsatellite instability-high MSS microsatellite stable OS overall survival PFS progression-free survival pMMR proficient MMR RASmt RAS mutated TMB tumor mutational burden TuLIS Tumor Lymphocytes Infiltrating Score WES whole exome...
Open in Who Shared Issue with article?
See all 16 licensed articles (17 Total)